Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 343

1.

[GRP78 expression in gastric cancer and its clinical significance].

Yang L, Yang SY, Ji JM, Cao YF, Ji CF, Ji JF, Xu WW, Wang JH.

Zhonghua Zhong Liu Za Zhi. 2013 Nov;35(11):837-42. Chinese.

PMID:
24447482
2.

Expression of GRP78 predicts taxane-based therapeutic resistance and recurrence of human gastric cancer.

Yang L, Yang S, Liu J, Wang X, Ji J, Cao Y, Lu K, Wang J, Gao Y.

Exp Mol Pathol. 2014 Apr;96(2):235-41. doi: 10.1016/j.yexmp.2014.02.011. Epub 2014 Mar 3.

PMID:
24602846
3.

Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas.

Zheng HC, Takahashi H, Li XH, Hara T, Masuda S, Guan YF, Takano Y.

Hum Pathol. 2008 Jul;39(7):1042-9. doi: 10.1016/j.humpath.2007.11.009. Epub 2008 May 14.

PMID:
18482745
4.

Abnormal expression of adhesion protein Bves is associated with gastric cancer progression and poor survival.

Luo D, Huang H, Lu ML, Zhao GF, Chang J, Zheng MY, Wang Y.

Pathol Oncol Res. 2012 Apr;18(2):491-7. doi: 10.1007/s12253-011-9472-x. Epub 2011 Nov 23.

PMID:
22109561
5.

P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy.

Díez M, Medrano MJ, Gutierrez A, López A, Mugüerza JM, Hernández P, Lozano O, Noguerales F, Ruíz A, Granell J.

Anticancer Res. 2000 Sep-Oct;20(5C):3929-33.

PMID:
11268479
6.

Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.

He MM, Zhang DS, Wang F, Wang ZQ, Luo HY, Ren C, Jin Y, Chen DL, Xu RH.

World J Gastroenterol. 2014 Jan 7;20(1):264-73. doi: 10.3748/wjg.v20.i1.264.

7.

[Impact of clinicopathological features and extent of lymph node dissection on the prognosis in early gastric cancer patients].

Wu H, Wang L, He YL, Xu JB, Cai SR, Ma JP, Chen CQ, Zhang XH, Zhan WH.

Zhonghua Zhong Liu Za Zhi. 2013 Jul;35(7):509-13. Chinese.

PMID:
24257302
9.

Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.

Okada K, Fujiwara Y, Takahashi T, Nakamura Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Mori M, Doki Y.

Ann Surg Oncol. 2013 Mar;20(3):1035-43. doi: 10.1245/s10434-012-2680-0. Epub 2012 Oct 2.

PMID:
23054116
10.

[Expression of HER-2 and leptin in gastric cancer and their clinical significance].

Geng YT, Qiu JR, Wang R, Su YT, Shu YQ, Yin YM.

Zhonghua Zhong Liu Za Zhi. 2011 Oct;33(10):764-9. Chinese.

PMID:
22335909
11.

Increased expression of DLX2 correlates with advanced stage of gastric adenocarcinoma.

Tang P, Huang H, Chang J, Zhao GF, Lu ML, Wang Y.

World J Gastroenterol. 2013 May 7;19(17):2697-703. doi: 10.3748/wjg.v19.i17.2697.

12.

[Expression and clinical significance of CD44v6 and sCD44v6 in gastric carcinoma].

Zhou DH, Ma ZM, Chen Y.

Zhonghua Zhong Liu Za Zhi. 2007 Nov;29(11):833-7. Chinese.

PMID:
18396641
13.

Prognostic factors for recurrence in stage II and III gastric cancer patients receiving a curative resection and postoperative adjuvant chemotherapy.

Tsujinaka T, Shiozaki H, Yano M, Kikkawa N, Takami M, Monden M.

Oncol Rep. 2001 Jan-Feb;8(1):33-8.

PMID:
11115565
14.

Aberrant loss of dickkopf-3 in gastric cancer: can it predict lymph node metastasis preoperatively?

Park JM, Kim MK, Chi KC, Kim JH, Lee SH, Lee EJ.

World J Surg. 2015 Apr;39(4):1018-25. doi: 10.1007/s00268-014-2886-3.

PMID:
25604390
15.

Lymphatic vascular invasion is an independent correlated factor for lymph node metastasis and the prognosis of resectable T2 gastric cancer patients.

Bu Z, Zheng Z, Li Z, Zhang L, Wu A, Wu X, Sun Y, Ji J.

Tumour Biol. 2013 Apr;34(2):1005-12. doi: 10.1007/s13277-012-0637-3. Epub 2013 Jan 6.

PMID:
23292920
16.

ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy.

De Dosso S, Zanellato E, Nucifora M, Boldorini R, Sonzogni A, Biffi R, Fazio N, Bucci E, Beretta O, Crippa S, Saletti P, Frattini M.

Cancer Chemother Pharmacol. 2013 Jul;72(1):159-65. doi: 10.1007/s00280-013-2181-2. Epub 2013 May 5.

PMID:
23645290
17.
18.

Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer.

Hwang JE, Hong JY, Kim K, Kim SH, Choi WY, Kim MJ, Jung SH, Shim HJ, Bae WK, Hwang EC, Lee KH, Lee JH, Cho SH, Chung IJ.

BMC Cancer. 2013 Sep 23;13:431. doi: 10.1186/1471-2407-13-431.

19.

[Clinical analysis of the current treatment status of gastric cancer in 636 patients].

Zhuang QX, Xu JM, Lin L, Ge FJ, Liu LJ, Wang Y, Zhao CH.

Zhonghua Zhong Liu Za Zhi. 2012 Apr;34(4):316-20. doi: 10.3760/cma.j.issn.0253-3766.2012.04.017. Chinese.

PMID:
22781048
20.

Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer.

Kim JW, Cho HJ, Kim M, Lee KH, Kim MA, Han SW, Oh DY, Lee HJ, Im SA, Kim TY, Yang HK, Kim WH, Bang YJ.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1435-43. doi: 10.1007/s00280-013-2141-x. Epub 2013 Apr 30.

PMID:
23633032
Items per page

Supplemental Content

Write to the Help Desk